Last update: May 27, 2021
Throughout the ongoing pandemic, Sanofi has joined forces to fight COVID-19 in every way possible. This includes developing two vaccine candidates to help prevent and control COVID-19.
Sanofi's two vaccine candidates
Scaling up manufacturing capabilities
Reality safety check
While the urgency of developing an effective vaccine cannot be ignored, Sanofi’s top priority is safety. Our CEO, Paul Hudson, pledged with eight other biopharma CEOs to develop potential vaccines in accordance with high ethical standards and sound scientific principles regarding clinical trials and manufacturing processes. Only vaccines that have passed an approved phase 3 trial will be submitted for approval or emergency-use authorization, a pledge that “will help ensure public confidence in the rigorous scientific and regulatory process by which COVID-19 vaccines are evaluated and may ultimately be approved. Our work, as always, is driven by science and our sense of responsibility,” said Paul. Solidarity is key to moving the fight against COVID-19 forward and, in time, to establishing a blueprint for collaboration and preparation for future pandemics.